anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Treatment of squamous cell carcinoma and adenocarcinoma of the esophagus has changed rapidly over the last decades due to implementation of multimodal cancer therapies such as radiotherapy or combined radiochemotherapy. Surgery, however, still is the mainstay of curative treatment options for this cancer entity. Due to the significant improvement in surgical technique and perioperative management, the postoperative mortality rate has fallen to about 5% with an estimated 5-year survival of 35%. Nevertheless, patients after esophagectomy are at high risk for local recurrence especially within the first 2 years after treatment. Independent risk factors for the development of carcinoma recurrence are incomplete resection (R1), extracapsular lymph node involvement and postoperative complications. Exfoliated, malignant cells remaining in luminal organs like the esophagus or colorectum could present another important risk factor for local recurrence especially at the site of anastomosis. In the treatment of rectal cancer, data have shown, that intraoperative rectal washout significantly reduces the risk of local recurrence from about 10% to 5%. For this reason, rectal washout during anterior resection has become a standard in many surgical institutions. Besides agents like cetrimide, sodium hypochlorite, formalin or saline, povidone-iodine has also been used for rectal mucosal application in prospective studies. Questions arise, weather similar positive outcomes could be achieved in esophageal surgery. The investigators hypothesize that esophageal washout with a povidone-iodine solution (Betaisodona®, Mundipharma) reduces the risk of local carcinoma recurrence after radical resection.
The invention discloses a specificity overexpression mouse model of a transduction iASPPsv cancer gene in a hemopoietic system and a preparation method and the use thereof. The method comprises the following steps of: establishing an hM HS21/45vav-iASPPsv plasmid, removing a prokaryotic expression vector part after the plasmid is subjected to the Hind III enzyme digestion, and standing the product for low-voltage electrophoresis over night after the linearization followed by glue cutting, recovery, purification and nucleic acid concentration regulation. By the method of microinjection, the transgenic vector, hM HS21/45vav-iASPPsv, is injected to a zygote of a C57 mouse, and the zygote is implanted in a uterus of a pseudopregnancy mouse. 19 to 21 days after the operation, a new mouse is born and subjected to ear cutting, numbering and tail cutting after 3 weeks. DNA is extracted from the tail to detect the integration of the target gene, iASPPsv, by using PCR. The specificity overexpression mouse model of the transduction iASPPsv cancer gene in hemopoietic system is obtained by using molecular biology, experimental zoology and the like to successfully establish an experimental method for detecting the amplification, oriented differentiation, migration, apoptosis and the like of hematopoietic stem/progenitor cells and lay a foundation for the mechanism research and targeted therapy for further explaining the transformation of normal hematopoietic stem/progenitor cells to tumor cells.
The utility model relates to a polyfluortetraethylene dental floss, comprising a floss body. The utility model is characterized in that the floss body is formed by rolling up the polyfluortetraethylene film with millipores and then pressing into a flat belt shape. The front end plane and the back end plane of the floss body of flat belt shape are provided with transverse strip rivels. When used, the utility model can take away the food residue, the soft tartar and the dental plaque in    the slit between the teeth easily, which has good and efficient effect of cleaning tooth adjacent face. The floss has good mouthfeel and long storage life. The user feels easy and pleased. The utility model is applicable to hospital, family and the like.
In the present invention there is disclosed a process for preparing 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole i.e.  omeprazole. The preparation process is characterized by reacting (4-methoxy-3,5-dimethyl-2-pyridyl)methyl alcohol with a chlorination agent under formation of (4-methoxy-3,5-dimethyl-2-pyridyl)methyl chloride, further reacting this intermediate with 2-mercapto-5-methoxybenzimidazole in the presence of a base for obtaining 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]thio-1H-benzimidazola and by reacting the intermediate thus formed with m-chloroperoxybenzoic acid. The novel process is characterized in that the whole reaction sequence is carried out without any isolation or purification of intermediates. Further that the reaction is carried out in a main solvent system common for the whole reaction sequence and inert to the reactants formed during the process and used in the process. The process according to the present inv
This invention describes the function of inophyllolide E2 for inhibiting SARs virus, and the application thereof. This invention also relates the method for preparing said compound by extracting inophylloidic fruit from Yunnan prov. of China. Said medicine is human-acceptable type, and contains inophyllolide E2 for anti-SARS virus. The research shows that: medium effective concentration EC50 for protecting VERO cells infected by SARS is 7.721 mg/L. Said iophyllolide E2 has no toxicity to VERO cells when its concentration is lower than 248 mg/L, with its IC 50=350.4 mg/L.
BACKGROUND: Smoking is a key cause of socioeconomic health inequalities. Vaping is considered less harmful than smoking and has become a popular smoking cessation aid, and therefore has potential to reduce inequalities in smoking.
METHODS: We used longitudinal data from 25 102 participants in waves 8-10 (2016 to early 2020) of the UK Household Longitudinal Study to examine how vaping affects socioeconomic inequalities in smoking cessation and relapse. Marginal structural models were used to investigate whether vaping mediates or moderates associations between educational attainment and smoking cessation and relapse over time. Multiple imputation and weights were used to adjust for missing data.
RESULTS: Respondents without degrees were less likely to stop smoking than those with a degree (OR: 0.65; 95% CI 0.54-0.77), and more likely to relapse (OR: 1.74; 95% CI 1.37-2.22), but this inequality in smoking cessation was not present among regular vapers (OR: 0.99; 95% CI 0.54-1.82). Sensitivity analyses suggested that this finding did not hold when comparing those with or without any qualifications. Inequalities in smoking relapse did not clearly differ by vaping status.
CONCLUSIONS: Vaping may be especially helpful as a cessation aid for smokers without degree level education and therefore may help reduce inequalities in smoking. Nevertheless, other supports or aids may be needed to reach the most disadvantaged (ie, those with no qualifications) and to help people avoid relapse after cessation, though we did not find clear evidence suggesting that vaping would increase inequalities in relapse.
Pyrazinamide should always be administered with other effective antituberculous drugs. It is administered for the initial 2 months of a 6-month or longer treatment regimen for drug-susceptible patients. Patients who are known or suspected to have drug-resistant disease should be treated with regimens individualized to their situation. Pyrazinamide frequently will be an important component of such therapy.

Patients with concomitant HIV infection may require longer courses of therapy. Physicians treating such patients should be alert to any revised recommendations from CDC for this group of patients.

Usual dose: Pyrazinamide is administered orally, 15 to 30 mg/kg once daily. Older regimens employed 3 to 4 divided doses daily, but most current recommendations are for once a day. Three grams per day should not be exceeded. The CDC recommendations do not exceed 2 g per day when given as a daily regimen (see table).

Alternatively, a twice weekly dosing regimen (50 to 70 mg/kg twice weekly based on lean body weight) has been developed to promote patient compliance with a regimen on an outpatient basis. In studies evaluating the twice weekly regimen, doses of pyrazinamide in excess of 3 g twice weekly have been administered. This exceeds the recommended maximum 3 g/daily dose. However, an increased incidence of adverse reactions has not been reported.

The table is taken from the CDC-American Thoracic Society joint recommendations: 4

Definition of abbreviations: PO = perorally; IM = intramuscularly.
There have been numerous randomized, double-blind controlled trials demonstrating the value of lamotrigine in the treatment of seizures. However, randomized trials take place in artificial experimental conditions with many restrictions imposed. There hasn't been much focus on positive effects on the patient, such as improvement in mood and level of alertness related to the drug. Other factors related to quality of life that affect the decision to continue or discontinue the drug are also important. Anecdotal experience suggests that lamotrigine is associated with increased alertness, enhanced energy levels and improved general sense of well-being. Observational studies that promote awareness of such distinguishing features and other aspects of efficacy are essential for guiding decision-making when prescribing anti-epileptic drugs.
Systems, methods, and instrumentalities are disclosed for using interrelated machine learning (ML) models (e.g., algorithms). The interrelated ML models may act collectively to perform complimentary portions of a surgical analysis. The ML models may be used at various locations. For example, ML models may be implemented in a facility network, a cloud network, an edge network, and/or the like. The location of the ML models may influence the type of data the ML models process. For example, ML models used outside a HIPAA boundary (e.g., cloud network) may process non-private and/or non-confidential information. The ML models may be used to feed their respective results into other ML models to provide a more complete result.
Macrophages are plastic immune cells that have varying functions dependent on stimulation from their environment. In a recent issue of Immunity, Do and colleagues demonstrated that activating mechanistic target of rapamycin complex 1 signaling in tumor macrophages alters their metabolism, localization, and function. Specifically, these tumor macrophages promote vascular remodeling that develops a hypoxic environment toxic to cancer cells. This culminates in a tangible reduction in tumor burden in a murine model of breast cancer. Their findings reveal a unique strategy to promote vascular remodeling through macrophage polarization and thereby highlight the intimate connections between macrophage metabolism and function. Additionally, their model highlights parallels between tumor progression and wound healing contexts while emphasizing the amplified effect of small perturbations to a tumor ecosystem.
<P>PROBLEM TO BE SOLVED: To provide a method for inhibiting aberrant splicing of a pre-mRNA molecule by using an antisense oligonucleotide, to develop a method for upregulating gene expression and to provide the antisense oligonucleotide useful for performing the method.  <P>SOLUTION: The method for inhibiting aberrant splicing of the pre-mRNA including a mutation is disclosed. The antisense oligonucleotide is hybridized to the pre-mRNA molecule to create a duplex molecule under a condition which permits splicing. The antisense oligonucleotide does not activate ribonuclease H, and is selected to block a constituent element of the aberrant set of splice elements created by the mutation, thus, the native intron is removed by the splicing and the first mRNA molecule encoding a native protein is produced. Oligonucleotides useful for performing the method are also provided.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Goal will be to attain \<7% of daily calories from saturated fat. Replace it with energy from monounsaturated fat.
Glioblastoma multiforme (GBM) is a highly heterogeneous brain tumor with limited treatment options. Recent studies revealed cellular heterogeneity and the potential for interconversion between distinct cell types on the basis of RNA sequencing and single-cell analyses. The ability of different cell types to adapt to their surrounding environment and undergo transformation significantly complicates the study and treatment of GBM. In this study, we reveal that HNRNPK-SUMO1 expression is predominantly found in the GBM infiltration area. SUMOylation of the K422 residue of HNRNPK interferes with its DNA binding ability, thereby disrupting downstream transcription, and ultimately leading to transitions between different states of glioblastoma stem cells. Although the proneural subtype is considered to have a better prognosis, transitioning towards this state promotes tumor invasion. These findings serve as a reminder to exercise caution when considering treatments targeting specific cellular subtypes.
A method for synoptic element structured reporting on a computing device is described. The method includes identifying a clinical context. The method also includes identifying a key question based on the identified clinical context. The method further includes obtaining an answer to the key question. The method additionally includes codifying the answer to produce a codified answer. The method also includes storing the codified answer in a database.
OBJECTIVE: Denmark went through various COVID-19 pandemic restrictions including periodic lockdowns from March 2020 to January 2022. All cancer screening programs were kept operational, yet access to clinicians for cervical screening was at times limited. We assessed the impact of the pandemic on cervical cancer screening activity in the Capital Region of Denmark.
METHODS: Cervical screening activity was defined as regular screening by invitation, opportunistic screening, and screening participation by HPV self-sampling. Activity was monitored during and post-pandemic and compared relatively to a 3-year pre-pandemic reference.
RESULTS AND CONCLUSIONS: The activity of cervical cancer screening was initially affected by the pandemic lockdowns, but increased activity during summer 2020 partly compensated this effect. Regular screening activity decreased 8.4% in 2020 and returned to pre-pandemic levels in 2021. During 2022 restrictions were removed and the decrease in activity was recorded to be 2.3%. Opportunistic screening activity was reduced by 14.3% in 2020 and 12.6% in 2021. A continued post-pandemic opportunistic screening activity reduction of 18.5% was observed, possibly related to changed patterns of primary health care use introduced during the pandemic. Screening by HPV self-sampling increased from 17.1% in the pre-pandemic period to 21.2% during the pandemic. Significantly more acceptance was recorded amongst older women (p < 0.0001). This increase mirrors the decrease in total clinician collected sample activity during the pandemic, where an increased reduction by age was observed. Post-pandemic HPV self-sampling participation decreased to 12.8%, possible reflecting a temporarily changed composition and motivation in the group of women invited for self-sampling.
PURPOSE:To provide an antienzyme containing 3,5-di-t-butyl-4-hydroxy-styrene derivative or its salt as an active component, effective to inhibit tyrosine kinase participating in the control of cell proliferation, and useful as a carcinostatic agent and anticarcinogenetic agent having low toxicity. CONSTITUTION:A tyrosine kinase inhibiting agent can be produced by using the compound of formula (R<1> is carboxy or carbamoyl; R<2> is 1-4C alkyl, CN, etc.) or its salt as an active component. The concrete example of the compound of formula is 3,5-di-t-butyl-4-hydroxy-alpha-hydroxyethylcinnamic acid, etc. The compound of formula is effective to inhibit tyrosine kinase participating in the proliferation and canceration of cell. It can be administered by oral, transintestinal or parenteral administration at a dose of preferably 20mg-5g/ day. The compound of formula can be produced by reacting 3,5-di-t-butyl-4- hydroxybenzaldehyde with the compound of formula II (Ar is aryl).
Measures tear film stability, and visual function will be taken before and after a sustained silent reading task. The reading task will take place over 30 minutes, and a comprehension assessment will be given after reading. After completion of the reading task, measures of corneal sensation and structural imaging will be performed. The results from each of 3 cohorts will be compared to ascertain the differences between those populations with and without dry eye.
The enjoyment of a fine wine, the odor of a ripe cheese, the memory of a long-lost grandmother brought back by the scent of her perfume, or the alarm we feel when we smell smoke are all produced by a functioning olfactory system. Interestingly, there are enormous individual differences in how we interpret these smells. Given almost any odor, some people will find it pleasant, others unpleasant. Ripe cheese or garlic may smell delicious to some, but repulsive to others. The scientific basis of this variation has not been well-studied. Despite the clear evidence for culture-based preferences for food and aromas, the nature-versus-nurture debate for smell remains unresolved. We believe there may be a genetic basis for our unique senses of smell. For example, some of us can smell methanethiol, the metabolite that is excreted in our urine after eating asparagus, whereas other people cannot. The Rockefeller University Smell Study seeks to recruit 400 normal subjects to track down the genetic basis of how we perceive smells. The study consists of up to two visits, each lasting up to 4 hours, in which we will test your perception of a variety of smells. On your first visit there will be a small blood sample taken (8.5 millileters) and your height and weight will be measured. If you are a woman of child-bearing age, we will ask you to provide a urine sample to test for pregnancy. If you are pregnant, you will not be permitted to participate in our study. You will fill out a short survey that asks some questions about yourself, your household, your personal habits, and your sense of smell. You will perform three different types of smell tests. In the first, you will be given two vials at a time and asked to tell us which contains an odor. In the second type of test, you will be asked to describe carefully your impression of three different odors. In the third type of test, you will be asked to rate odors according to their strength and pleasantness. All odorants will be presented to you in glass jars. You will be asked to smell odors in several hundred jars.
Use AIRVOTM2 (Fisher \& Paykel, Auckland, New Zealand), select the output gas temperature of 37°C, monitor and maintain SpO2 between 94% and 100%, and adjust the output gas flow rate of the therapy device to 40L/min, 50L/min and 60L/min, respectively. min, measure the actual gas flow rate value and the gas flow rate loss difference before and after each flow rate horizontal pipeline is connected to the conventional exhalation joint (matching special exhalation joint), and measure the gas temperature and humidity near the patient end of the pipeline at the corresponding gas flow rate.
TALTZ may increase the risk of infection. In clinical trials in adult patients with plaque psoriasis, the TALTZ group had a higher rate of infections than the placebo group (27% vs. 23%). Upper respiratory tract infections, oral candidiasis, conjunctivitis and tinea infections occurred more frequently in the TALTZ group than in the placebo group. A similar increase in risk of infection was seen in placebo-controlled trials in patients with pediatric psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis [see Adverse Reactions (6.1)]. 

In the postmarketing setting, serious bacterial, viral, and fungal opportunistic infections have been reported in patients receiving IL-17 inhibitors including TALTZ. Instruct patients treated with TALTZ to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a serious infection or is not responding to standard therapy, monitor the patient closely and discontinue TALTZ until the infection resolves.
The invention relates to a human anti-hepatitis B virus surface antibody as well as a preparation method and application thereof. A specific hepatitis B antibody with relatively high affinity activity on hepatitis B virus antigens can be obtained by virtue of antigen-antibody binding activity screening, wherein an amino acid sequence of a light chain variable region of the antibody is shown in SEQ ID No. 1 or SEQ ID No. 2, and an amino acid sequence of a heavy chain variable region of the antibody is shown in SEQ ID No. 3 or SEQ ID No. 4. According to the human anti-hepatitis B virus surface antibody disclosed by the invention, antibody mutation hot spots are analyzed by virtue of a protein molecule modeling technology and are subjected to saturation mutation by taking an amino acid as a unit so as to construct a mutant library and perform biological verification, and thus optimization of the antibody can be achieved. The human anti-hepatitis B virus surface antibody disclosed by the invention can be used for laying a foundation for preventing hepatitis B virus infection and performing treatment research at the same time, so that the human anti-hepatitis B virus surface antibody can be applied to the prevention and treatment of liver diseases caused by hepatitis B virus infection clinically.
This is a small, one-armed pilot study testing a physical activity intervention for pregnant patients with diabetes. The intervention will use both counseling and technology (a FitBit physical activity tracker and smartphone app) to create an individualized, interactive program for each patient. The primary aims of the study are to assess the feasibility of recruiting patients and implementing the program in the clinical setting, and the acceptability of the program for patients and clinicians. Participants will receive a counseling session based on the principles of motivational interviewing to help them set physical activity and step goals, then the interventionist will help them personalize the Fitbit app to their goals. Participants are instructed to continue adaptive goal setting and email their goals and activity weekly to their physicians. In addition to assessing feasibility and acceptability, we will also evaluate change in activity to explore potential efficacy.